Vogenx (NASDAQ:VOGX) reported a third-quarter 2026 net loss of $4,907,603 as it advanced mizagliflozin development following its August IPO. Loss per basic and diluted share was $0.47, versus $0.05 a year earlier, when net loss was $284,407. Research and development expenses rose to $1,079,000 from $124,813; general and administrative expenses increased to $703,736 from $177,664. A $3,436,669 warrant valuation expense also contributed to the loss.
The IPO generated approximately $84.4 million in net proceeds, with 7,187,500 shares sold at $13.00 each. Cash, cash equivalents and marketable securities totaled $82.1 million at September 30, versus $601 thousand at December 31, 2025. In October, Vogenx initiated the Phase 2b EMERGE study for post-bariatric hypoglycemia, with results expected in the second half of 2027. The company plans a Phase 2 gastroparesis study in the first half of 2027.
Vogenx (VOGX) has initiated EMERGE, a Phase 2b trial evaluating investigational mizagliflozin for low blood sugar following bariatric surgery.
The randomized, double-blind, placebo-controlled study plans to enroll approximately 36 adults. After a three-week run-in period, eligible participants will receive oral mizagliflozin 5 mg, 10 mg or placebo three times daily for 28 days. The primary endpoint is the number of combined Level 2 and Level 3 hypoglycemic events. Safety and tolerability will also be assessed, with continuous glucose monitoring during treatment. Vogenx expects approximately 10 U.S. sites.
Earlier clinical studies showed improvements in Level 2 and Level 3 hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). Across clinical studies, no drug-related serious adverse events or discontinuations or withdrawals were reported. No FDA-approved therapy currently treats PBH.
Vogenx (VOGX) appointed board member Richard Gorman as Chief Commercial Officer, effective October 12, 2026, in a newly created role. He will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia and gastroparesis, plus long-range pipeline planning. Initially, he will also oversee business development, including partnering and licensing strategy.
Gorman will resign from the board and its committees when he joins management. Vogenx will search for a new independent director. The company said it is preparing to move mizagliflozin into later-stage development.
Vogenx (VOGX) has appointed industry executive Ken Toombs to its Board of Directors and Audit Committee Chair, effective September 21, 2026.
Toombs brings three decades of global professional services experience, including senior leadership roles at PA Consulting, Infosys Consulting, Capgemini Consulting, PricewaterhouseCoopers and IBM, with a background spanning healthcare and life sciences. Vogenx is a clinical-stage biopharmaceutical company developing mizagliflozin, an investigational first-in-class SGLT1 inhibitor, for post-bariatric hypoglycemia (PBH), gastroparesis and GIP-dependent Cushing's Syndrome. Mizagliflozin has been tested in more than 500 subjects across 10 clinical studies and has shown statistically significant effects on postprandial glucose absorption, GIP and insulin secretion, as well as improvements in PBH-related hypoglycemia measures.
Vogenx (NASDAQ: VOGX), a clinical-stage biopharmaceutical company targeting diseases linked to metabolic dysfunction, completed an initial public offering of $81.3 million. The IPO comprised 6,250,000 shares of common stock at $13.00 per share, the high end of the proposed range, with all shares sold by Vogenx.
Gross proceeds to Vogenx were approximately $81.3 million before underwriting discounts, commissions, and expenses. Vogenx shares began trading on the Nasdaq Capital Market under the ticker “VOGX” on August 12, 2026, and the offering closed on August 13, 2026. JonesTrading served as sole book-running manager.
Vogenx (NASDAQ:VOGX), a clinical-stage biopharmaceutical company targeting metabolic disorders such as post-bariatric hypoglycemia (PBH) and gastroparesis, closed its initial public offering of 6,250,000 common shares at $13.00 per share, generating gross proceeds of approximately $81.3 million before fees and expenses.
Vogenx’s stock began trading on the Nasdaq Capital Market on August 12, 2026 under the ticker VOGX. The company granted underwriters a 45-day option to buy up to an additional 937,500 shares. Vogenx’s lead candidate mizagliflozin is being developed for PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Vogenx (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on metabolic diseases such as post-bariatric hypoglycemia (PBH) and gastroparesis, priced its initial public offering of 6,250,000 common shares at $13.00 per share, at the high end of the range, for expected gross proceeds of approximately $81.3 million before fees and expenses.
The common stock is expected to begin trading on the Nasdaq Capital Market on August 12, 2026, under ticker “VOGX”, with closing expected August 13, 2026, subject to customary conditions. Underwriters have a 45-day option to buy up to 937,500 additional shares at the offering price, less discounts and commissions.